TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6422096

Group type: EXPERIMENTAL
Intervention: Combined modality therapy of nonspecific and host mediate immunotherapy and chemotherapy as an adjuvant to surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 0
Study: 31435980

Group type: EXPERIMENTAL
Intervention: Posttreatment functional status assessment (diet, public eating, speech)
Number of subjects: 495
Study: 28387889

Group type: COMPARATOR
Intervention: Propofol (Group B)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ketamine (Group C)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Conventional treatment (Group A)
Number of subjects: 63
Study: 25926152

Group type: EXPERIMENTAL
Intervention: Dural splitting decompression (DSD)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Posterior fossa decompression with duraplasty (PFDD)
Number of subjects: 160
Study: 24102165

Group type: EXPERIMENTAL
Intervention: GaAs laser therapy (peak power 10 W; pulse frequency 3000 Hz; average power 0.012 W; wavelength 980 nm; irradiation duration 300 sec; dose 12.73 J/cm²)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham laser treatment (control group)
Number of subjects: 60
Study: 21376050

Group type: EXPERIMENTAL
Intervention: Drinking 3 or more cups/day of coffee
Number of subjects: 885
Study: 19156018

Group type: EXPERIMENTAL
Intervention: Intervention delivered by Speech and Language Pathologists/Therapists targeting dysarthric speech
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 0
Study: 17032921

Group type: EXPERIMENTAL
Intervention: Salvage therapy after relapse
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Younger age (under 20 years)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Short duration of first remission (CR1)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: HSCT after relapse (in a selected subgroup)
Number of subjects: 609
Study: 15326083

Group type: EXPERIMENTAL
Intervention: Perindopril (4 to 8 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg per day)
Number of subjects: 30
Study: 12002730

Group type: EXPERIMENTAL
Intervention: Fexofenadine 360 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Promethazine 30 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9619533

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of gonadotrophins
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) administration of gonadotrophins
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both s.c. and i.m. administration of gonadotrophins
Number of subjects: 71
Study: 7613555

Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg b.i.d.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Doxofylline (400 mg t.i.d.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theophylline and Doxofylline
Number of subjects: 8
Study: 2198208

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg after the evening meal (R-P group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo before bedtime (P-R group)
Number of subjects: 87
Study: 734639

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 5
Study: 6282482

Group type: EXPERIMENTAL
Intervention: ACE (Doxorubicin 45 mg/m2 i.v. day 1, Cyclophosphamide 1.0 mg/m2 i.v. day 1, VP16-213 50 mg/m2/day i.v. days 1-5)
Number of subjects: 174

Group type: COMPARATOR
Intervention: ACE (Doxorubicin, Cyclophosphamide, VP16-213)
Number of subjects: 174
Study: 31204273

Group type: EXPERIMENTAL
Intervention: Thermal suit T‐Balance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Forced air warming (FAW)
Number of subjects: 30
Study: 29452814

Group type: EXPERIMENTAL
Intervention: Awake removal of LMA
Number of subjects: 290

Group type: COMPARATOR
Intervention: Deep removal of LMA
Number of subjects: 290
Study: 26718305

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 21824187

Group type: EXPERIMENTAL
Intervention: Practice guidelines nutritional care (n = 85)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual nutritional care (n = 85)
Number of subjects: 170
Study: 21142856

Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17662432

Group type: EXPERIMENTAL
Intervention: Artiflex pIOL
Number of subjects: 20
Study: 15327930

Group type: EXPERIMENTAL
Intervention: Autobiographical memory test with varying levels of retrieval support
Number of subjects: 1

Group type: COMPARATOR
Intervention: Visual imagery tests
Number of subjects: 1
Study: 11782042

Group type: EXPERIMENTAL
Intervention: Random-effects model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marginal models (GEE, WGEE, ML)
Number of subjects: 0
Study: 9059684

Group type: EXPERIMENTAL
Intervention: 250 mg terbinafine daily for 3 months
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 250 mg terbinafine daily for 3 or 6 months
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 148
Study: 8112373

Group type: EXPERIMENTAL
Intervention: Nicorandil 0.05 microgram.kg‐1.min‐1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nicorandil 0.10 microgram.kg‐1.min‐1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nicorandil 0.20 microgram.kg‐1.min‐1
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nicorandil (all doses)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2873000

Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined therapy with theophylline and beta-adrenergic agonist
Number of subjects: 15
Study: 28060048

Group type: EXPERIMENTAL
Intervention: 2 doses of inactivated hepatitis A vaccine (group 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1 dose of inactivated hepatitis A vaccine plus 1 dose of combined hepatitis A and B vaccine (group 2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 2 doses of combined hepatitis A and B vaccine (group 3)
Number of subjects: 3
Study: 25454689

Group type: EXPERIMENTAL
Intervention: Loading dose of 12 mg I.V. ibandronate on day 1 then oral ibandronate 50 mg daily (arm A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard oral therapy of 50 mg ibandronate daily from day 1 (arm B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Loading dose of 12 mg I.V. ibandronate (arm A)
Number of subjects: 34
Study: 24973875

Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 180

Group type: COMPARATOR
Intervention: propofol/alfentanil
Number of subjects: 180

Group type: COMPARATOR
Intervention: midazolam/fentanyl
Number of subjects: 180
Study: 23062542

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with an implantable cardioverter‐defibrillator (ICD)
Number of subjects: 1699

Group type: COMPARATOR
Intervention: ICD only
Number of subjects: 1699
Study: 19583039

Group type: EXPERIMENTAL
Intervention: 3% neem
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2% triclosan
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite
Number of subjects: 40

Group type: COMPARATOR
Intervention: distilled water (control)
Number of subjects: 40
Study: 17223936

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS) at S3
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS) at S2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continuous sacral nerve stimulation (SNS) over 3 weeks
Number of subjects: 8
Study: 15774402

Group type: COMPARATOR
Intervention: Green land-based activities, training and social support; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Qualitative interviews and focus group discussions; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 11464350

Group type: EXPERIMENTAL
Intervention: Gabapentin 1,200 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9670112

Group type: EXPERIMENTAL
Intervention: Training group (n = 21) - physical training including exercises on bicycle ergometer for 30 minutes (5 times a week), overall-conditioning exercises for 30 minutes daily, and 30 to 60 minutes of walking each day.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n = 11) - discharged home for 3 weeks with identical dietary instructions, no physical training.
Number of subjects: 32
Study: 8152756

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Powder-free surgical gloves with postoperative injections of 5-fluorouracil
Number of subjects: 148

Group type: COMPARATOR
Intervention: Powdered surgical gloves
Number of subjects: 148
Study: 3062134

Group type: EXPERIMENTAL
Intervention: Azathioprine alone (Aza)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azathioprine in combination with steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azathioprine treatment
Number of subjects: 0
Study: 31962378

Group type: EXPERIMENTAL
Intervention: WBISI120
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: WBISI
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 148
Study: 31774052

Group type: EXPERIMENTAL
Intervention: Nasal lavage with mupirocin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal lavage without mupirocin
Number of subjects: 20
Study: 28634690

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (LHR) with large-pore polypropylene mesh
Number of subjects: 37

Group type: COMPARATOR
Intervention: Open hernia repair (OHR) with retromuscular small-pore heavy-weight mesh
Number of subjects: 37
Study: 25573141

Group type: EXPERIMENTAL
Intervention: Moldable positioner
Number of subjects: 62

Group type: COMPARATOR
Intervention: Moldable positioner and cranial cup
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cranial cup
Number of subjects: 62
Study: 23562699

Group type: EXPERIMENTAL
Intervention: Dual coil ICD leads
Number of subjects: 811

Group type: COMPARATOR
Intervention: Single coil ICD leads
Number of subjects: 811
Study: 21375428

Group type: EXPERIMENTAL
Intervention: A‐polysiloxane soft cushion material
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polyether impression material
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deflexion
Number of subjects: 30
Study: 19634962

Group type: EXPERIMENTAL
Intervention: Feedback condition
Number of subjects: 410

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 410
Study: 17473728

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 26
Study: 15272659

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish (Cervitec), reapplied every 3 months
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 181
Study: 11579006

Group type: EXPERIMENTAL
Intervention: Routine care integrated with motivational interviewing, cognitive behavior therapy, and family intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 9601172

Group type: EXPERIMENTAL
Intervention: All‐Bond 2 dental adhesive and Z100 composite resin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: A.R.T. Bond and Brilliant Dentin composite
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Prisma Universal Bond 3 and Variglass VLC polyacid‐modified composite resin
Number of subjects: 23
Study: 8129387

Group type: EXPERIMENTAL
Intervention: 1 mg/day CGS16949A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg/day CGS16949A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 mg/day CGS16949A
Number of subjects: 0
Study: 2679685

Group type: EXPERIMENTAL
Intervention: Artificial intelligence techniques implemented on a computer
Number of subjects: 150

Group type: COMPARATOR
Intervention: Clinicians
Number of subjects: 150
Study: 31816338

Group type: EXPERIMENTAL
Intervention: Healthiness label anchored to the left
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-calorie label presented on the right
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pleasant choice key on the right
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-calorie food presented on the left
Number of subjects: 0
Study: 30453316

Group type: EXPERIMENTAL
Intervention: Treatment condition (Sketch and Speak intervention)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 44
Study: 28120524

Group type: COMPARATOR
Intervention: Test intervention
Number of subjects: 0
Study: 26079469

Group type: EXPERIMENTAL
Intervention: Immediate insertion of contraceptive implant
Number of subjects: 414

Group type: COMPARATOR
Intervention: Delayed insertion of contraceptive implant
Number of subjects: 414
Study: 23561463

Group type: EXPERIMENTAL
Intervention: Practical prescription information or services
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: Combination prescription information or services
Number of subjects: 3940

Group type: EXPERIMENTAL
Intervention: Practical prescription information or services (for subjects prescribed a drug that treats an underlying condition)
Number of subjects: 3940

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3940
Study: 21765809

Group type: EXPERIMENTAL
Intervention: LED fluorescence microscopy (LED-FM)
Number of subjects: 2355

Group type: COMPARATOR
Intervention: ZN smear microscopy
Number of subjects: 2355

Group type: EXPERIMENTAL
Intervention: Three LED-FM smears
Number of subjects: 2355

Group type: COMPARATOR
Intervention: Three ZN smears
Number of subjects: 2355
Study: 19138461

Group type: EXPERIMENTAL
Intervention: Two-question screen
Number of subjects: 204

Group type: COMPARATOR
Intervention: CIS-R (Revised Clinical Interview Schedule)
Number of subjects: 204
Study: 16700681

Group type: EXPERIMENTAL
Intervention: Forced-air warming blanket
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care warmed cotton blankets
Number of subjects: 62
Study: 15500134

Group type: EXPERIMENTAL
Intervention: RAS blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11579011

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg t.i.d. for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 14
Study: 9649259

Group type: EXPERIMENTAL
Intervention: 100 mg testosterone via intramuscular injection once a week for 15 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 250 mg testosterone via intramuscular injection once a week for 15 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 500 mg testosterone via intramuscular injection once a week for 15 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Total semen PSA levels decreased following administration of testosterone
Number of subjects: 31
Study: 1863126

Group type: EXPERIMENTAL
Intervention: Postural support with specific hip support during intensive care
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 6848894

Group type: EXPERIMENTAL
Intervention: Running program (average at least 8 miles per week)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 81
Study: 31401679

Group type: EXPERIMENTAL
Intervention: Cod intake (750 g/week for 8 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Salmon intake (750 g/week for 8 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (fish-free diet for 8 weeks)
Number of subjects: 62
Study: 30935953

Group type: EXPERIMENTAL
Intervention: R-pina (375 mg/m2 rituximab plus 2.4 mg/kg pinatuzumab vedotin)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: R-pola (375 mg/m2 rituximab plus 2.4 mg/kg polatuzumab vedotin)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: R-pina
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: R-pola
Number of subjects: 123
Study: 28556917

Group type: EXPERIMENTAL
Intervention: AML02 protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AML02 protocol (low-risk AML)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AML97 protocol
Number of subjects: 0
Study: 28077162

Group type: EXPERIMENTAL
Intervention: Fixed inhaled nitrous oxide/oxygen mixture
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Standard pain treatment (oral immediate-release morphine) plus nitrous oxide/oxygen mixture
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard pain treatment (oral immediate-release morphine) plus oxygen
Number of subjects: 240
Study: 23718718

Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch (15 mg/16 hour)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Varenicline plus placebo patch
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch
Number of subjects: 117
Study: 21360754

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Valproate treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overall sample (Lithium and Valproate)
Number of subjects: 100
Study: 18955565

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) followed by autologous purged stem cell transplantation (ASCT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 172
Study: 17158144

Group type: EXPERIMENTAL
Intervention: Radiant warmer
Number of subjects: 62

Group type: COMPARATOR
Intervention: Incubator
Number of subjects: 62
Study: 15043562

Group type: EXPERIMENTAL
Intervention: Hemosoft software for RBC ordering based on Hb content
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hemosoft software
Number of subjects: 51
Study: 11915269

Group type: EXPERIMENTAL
Intervention: Wheelchair biking therapy for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 10443306

Group type: EXPERIMENTAL
Intervention: Endoscopic method (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Classical method (Group A)
Number of subjects: 120
Study: 7982137

Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Vecuronium 0.1 mg/kg without diazepam)
Number of subjects: 20
Study: 2735178

Group type: EXPERIMENTAL
Intervention: Sighing during mechanical ventilation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard anesthetic without sighing
Number of subjects: 14
Study: 807170

Group type: EXPERIMENTAL
Intervention: Dudrick's method (20% glucose and a nitrogen source)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intralipid method (12% glucose, a nitrogen source and soybean fat emulsion)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Babson's method (12% glucose, a nitrogen source and 1% alcohol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Parenteral fat free nutrition (primary caloric source glucose)
Number of subjects: 6
Study: 30228338

Group type: EXPERIMENTAL
Intervention: Sequential seeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single stage seeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Greedy approach
Number of subjects: 0
Study: 28258601

Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (MPS)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) and Prednisolone (Pred)
Number of subjects: 361
Study: 26314577

Group type: EXPERIMENTAL
Intervention: Personalised multidimensional physical activity feedback and self-monitoring alongside trainer-supportive sessions
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care from general practitioner (GP) and standardised messages about physical activity for health
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Personalised feedback regarding the multidimensional nature of physical activity
Number of subjects: 216
Study: 23201472

Group type: EXPERIMENTAL
Intervention: GM+G-CSF
Number of subjects: 50

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 50
Study: 18421508

Group type: COMPARATOR
Intervention: Model A (traditional counseling/testing)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Model B (nurse‐initiated screening, traditional counseling/testing)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Model C (nurse‐initiated screening, streamlined counseling/rapid testing)
Number of subjects: 251
Study: 16555172

Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment (NPT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Readmission status
Number of subjects: 91
Study: 12669307

Group type: EXPERIMENTAL
Intervention: Elevated magnetic field exposure (magnetic flux density >or= 0.2 microT, or residential distance from major power lines <or= 100 m)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Background magnetic field exposure (magnetic flux density < 0.2 microT or > 100 m from major power lines)
Number of subjects: 577
Study: 10746118

Group type: EXPERIMENTAL
Intervention: Multi-component interventions targeting major risk factors for falls (education, exercise, home safety advice, medical assessment)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (information session only)
Number of subjects: 252
Study: 9172113

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy system (intraabdominal fan retractor and electrically powered mechanical arm)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard CO2 pneumoperitoneum laparoscopy
Number of subjects: 18
Study: 7527608

Group type: EXPERIMENTAL
Intervention: Somatostatin (125 micrograms/hour)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30181203

Group type: EXPERIMENTAL
Intervention: Tailored phone intervention
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Tailored Web + phone intervention
Number of subjects: 1196

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1196
Study: 26272687

Group type: EXPERIMENTAL
Intervention: Intracervical laminaria dilator
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (200 μg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Mechanical dilation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 150